StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $61.94 | $63.64 | +2.74% | 0.9M |
| 05-19 | $63.29 | $63.77 | +0.76% | 0.5M |
| 05-20 | $63.78 | $64.49 | +1.11% | 0.6M |
| 05-21 | $63.97 | $63.63 | -0.53% | 0.4M |
| 05-22 | $63.73 | $64.17 | +0.69% | 0.4M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $381.88M | $1.52B | $1.12B | $737.81M |
Operating Income | $44.16M | $184.72M | $130.53M | $87.91M |
Net Income | $40.99M | $128.49M | $90.48M | $32.58M |
EPS (Diluted) | $0.68 | $2.13 | $1.49 | $1.03 |
Total Assets | $2.72B | $2.69B | $2.63B | $2.59B |
Total Liabilities | $1.09B | $1.10B | $1.10B | $1.10B |
Cash & Equivalents | $488.08M | $446.40M | $392.46M | $341.82M |
Free Cash Flow OCF − CapEx | $24.67M | $215.66M | $141.61M | $89.07M |
Shares Outstanding | 59.66M | 59.42M | 59.29M | 59.22M |